The Estée Lauder Companies Announces Brand Leadership Promotions
1.7.2021 15:30:00 EEST | Business Wire | Press release
The Estée Lauder Companies (NYSE:EL) announced today the promotions of two brand leaders – Michelle Freyre has been promoted to Global Brand President, Clinique, and Glenn Evans has been promoted to Global Brand President, Smashbox and GLAMGLOW. The promotions are effective July 1, 2021, and both leaders will continue to report directly to John Demsey, Executive Group President, The Estée Lauder Companies (ELC).
“Michelle and Glenn are both incredibly dynamic leaders who have beautifully steered their respective brands through the challenges of the past year,” said John Demsey. “I am particularly proud of how effectively they have balanced the needs of the business while being truly thoughtful and empathetic leaders to their brand teams. Their promotions are both very well-deserved.”
Michelle Freyre Has Been Promoted to Global Brand President, Clinique
A dynamic leader with deep experience leading a variety of beauty brands across categories and channels, Michelle’s promotion to Global Brand President, Clinique, recognizes her outstanding and visionary leadership in returning Clinique to global growth. She was appointed Senior Vice President/Global General Manager, Clinique in June 2020, and since then has made a significant impact on Clinique’s brand positioning, driving double digit growth for hero products, as well as redefining the innovation strategy behind Clinique’s hero franchises. She has also driven Clinique’s acceleration in Online to be the #1 ELC brand in North America in that channel, while delivering the Clinique High-Touch experience at scale globally. Her inspirational leadership, deep expertise in beauty and skin care, together with her strong passion for connecting with global consumers, makes her uniquely suited to continue to lead Clinique in its next chapter of growth.
Michelle joined ELC from Johnson & Johnson in 2020, where she had an impressive 20-year career holding various leadership roles within its Consumer Health Products division, most recently serving as President, U.S. Beauty. In this role, she was responsible for the company’s portfolio of Beauty brands at the time, and led the successful performance and growth of many brands. Prior to that, she served as the General Manager of Neutrogena at J&J, and as the leader of the company’s Los Angeles campus.
Michelle is passionate about talent development and has a proven track record of fostering workplaces that embrace inclusion and diversity. She has received several industry awards and honors in recognition of her exceptional career, including being named to Fortune’s 2018 “50 Most Powerful Latinas in Business.”Michelle is the Executive Sponsor of Hispanic Connections (HiC) ERG and is actively mentoring diverse talent across ELC.
Glenn Evans Has Been Promoted to Global Brand President, Smashbox and GLAMGLOW
With more than 30 years of strategic, operational and brand-building experience, Glenn is an exceptional, values-driven brand leader with an impressive track record of delivering consistent results. As Senior Vice President/Global General Manager, Smashbox and GLAMGLOW, Glenn has successfully led both brands, capturing operational and supply chain synergies between them, optimizing their global brand and regional go-to-market structures and improving A&P effectiveness.
As Global Brand President, Glenn will continue to lead Smashbox and GLAMGLOW into their next phases of sustainable growth, focusing on product innovations with a consumer-led, online-centric, digital-first approach, as well as continuous transformation to evolve ahead of the changing retail landscape. A dynamic and energetic leader, Glenn will also continue to leverage his passion for developing top talent across both brand teams.
Since being named Senior Vice President and General Manager, Smashbox, in 2019, Glenn has led the brand’s repositioning strategy to drive appeal with both new and loyal consumers while staying true to the brand’s core studio heritage. Under his leadership, the brand reinforced its number one ranking in U.S. prestige Face Primers, achieved top rankings in prestige Face Primers in key global markets, and attracted new consumers with the success of Smashbox Halo All-in-One Tinted Moisturizer.
Before his role at Smashbox, Glenn was Senior Vice President, Leading Beauty Forward, where he led the successful global implementation of Leading Beauty Forward and OneSource, which have helped to fuel the company’s multiple engines of growth strategy. Prior to that role, Glenn was SVP, Global Supply Chain, during which time he established and led the Global Supply Chain Center of Excellence for six years, and played a leadership role in integrating and enhancing best-in-class capabilities across the organization.
Since 2018, Glenn has served as an Executive Sponsor of wELCome, ELC’s Employee Resource Group for LGBTQIA+ employees. He continues to act as a passionate advocate for Inclusion & Diversity across the Company. Glenn recently announced the creation of the West Coast chapter of wELCcome and he also sponsors the Smashbox & GLAMGLOW Multi-Ethnic Advisory Board, an employee-led group within the brands that aims to ensure diverse voices are amplified during key moments of decision-making.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-C
ELC-L
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005234/en/
Contact information
Investor Relations:
Rainey Mancini
(212) 284-3049
rmancini@estee.com
Media Relations:
Jill Marvin
(212) 572-4438
jimarvin@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release
In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 12:21:00 EEST | Press release
The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrate that personalising treatment decisions for patients with early-stage (stage II to IIIA) HER2-positive BC using the HER2DX genomic diagnostic assay can improve pat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
